Monday, December 23, 2024
HomeTagsHfCas12Max

hfCas12Max

HuidaGene and Synthego Announce Licensing Agreement on Next-Generation Gene Editing Enzyme, hfCas12Max

HuidaGene Therapeutics, a global clinical-stage biotechnology company focused on advancing CRISPR-based genomic medicines, and Synthego Corporation, a leading provider of innovative CRISPR solutions for...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics